Zaburzenia neuropsychiczne u chorych z przewlekłą chorobą nerek ze szczególnym uwzględnieniem autosomalnie dominującej wielotorbielowatości nerek Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Andrzej Wacław Kulesza
Bartosz Łoza

Abstrakt

Zaburzenia psychiczne często towarzyszą pacjentom cierpiącym z powodu różnych somatycznych chorób przewlekłych, co w szczególnym stopniu dotyczy przewlekłej choroby nerek. Rodzaj i nasilenie zaburzeń zależą od stopnia zaawansowania choroby, jej powikłań, chorób współistniejących oraz przyjmowanych przez pacjenta leków. Część zaburzeń, takich jak majaczenie, omamy czy cechy encefalopatii mocznicowej, występuje przede wszystkim u chorych ze schyłkową niewydolnością nerek. Inne częste zaburzenia, takie jak depresja i zaburzenia lękowe, pojawiają się na każdym etapie choroby, jednak z największą częstością u chorych poddawanych terapii nerkozastępczej. Wśród przyczyn przewlekłej choroby nerek na szczególną uwagę zasługuje autosomalnie dominująca wielotorbielowatość nerek ze względu na częstość jej występowania, dziedziczny charakter i związany z nią wysoki na tle innych przyczyn przewlekłej choroby nerek odsetek towarzyszących chorób psychicznych. Mimo częstego współwystępowania depresji, zaburzeń lękowych oraz innych chorób pozostających w kręgu zainteresowań psychiatrii wciąż odsetek chorych nefrologicznych, u których rozpoznano zaburzenie psychiczne oraz rozpoczęto jego leczenie, jest w tej populacji stosunkowo niewielki. W niniejszym artykule omawiamy najczęstsze zaburzenia psychiczne występujące u chorych z przewlekłą chorobą nerek, ich wpływ na leczenie i rokowanie, ze szczególnym uwzględnieniem autosomalnie dominującej wielotorbielowatości nerek.

##plugins.themes.bootstrap3.article.details##

Dział
Artykuły

Bibliografia

1. Dudek D, Sobański J. Mental disorders in somatic diseases: psychopatology and tratement. Pol Arch Med Wewn 2012; 122(12): 624-629.
2. Kimmel PL, Thamer M, Richard CM, Ray NF. Psychiatric illness in patients with end-stage renal disease. Am J Med 1998; 105(3): 214-221.
3. Cukor D, Coplan J, Brown C et al. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol 2007; 2: 484-490.
4. Pérez Domínguez TS, Buset Rios N, Rodriguez Esparragon F et al. Psychonephrology: Psychological aspects in autosomal dominant polycistic kidney disease. Nefrologia 2011; 31(6): 716-722.
5. Finkelstein FO, Finkelstein SH. Depression in chronic dialysis patients: assessment and treatment. Nephrol Dial Transplant 2000; 15: 1911-1913.
6. Waraich P, Goldner EM, Somers JM et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004; 49: 124-138.
7. Cohen SD, Norris L, Acquaviva K et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol 2007; 2: 1332-1342.
8. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011; 13: 7-23.
9. Joynt KE, Whellan DJ, O’Connor CM. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 2003; 54: 248-261.
10. Frasure-Smith N, Lespérance F, Habra M et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation 2009; 20: 134-140.
11. Burton HJ, Kline SA, Lindsay RM et al. The relationship of depression to survival in chronic renal failure. Psychosom Med 1986; 48: 261-269.
12. Arapaslan B, Soykan A, Soykan C et al. Cross-sectional assessment of psychiatric disorders in renal transplantation patients in Turkey: a preliminary study. Transplantation Proceedings 2004; 36: 1419-1421.
13. Saglimbene V, Palmer S, Scardapane M et al. Depression and allcause and cardiovascular mortality in patients on haemodialysis: a multinational cohort study. Nephrol Dial Transplant 2017; 32(2): 377-384.
14. Hedayati SS, Bosworth HB, Briley LP et al. Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int 2008; 74: 930-936.
15. Palmer S, Vecchio M, Craig JC et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int 2013; 84: 179-191.
16. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol 2010; 5(9): 1566-1573.
17. Panagopoulou A, Hardalias A, Berati S, Fourtounas C. Psycho-social issues and quality of life in patients on renal replacement therapy. Saudi J Kidney Dis Transpl 2009; 20: 212-218.
18. Masoumi M, Naini AE, Aghaghazvini R et al. Sleep quality in patients on maintenance hemodialysis and peritoneal dialysis. Int J Prev Med 2013; 4: 165-172.
19. Griffin KW, Wadhwa NK, Friend R, Suh H, Howell N, Cabralda T et al. Comparison of quality of life in hemodialysis and peritoneal dialysis patients. Adv Perit Dial 1994; 10: 104-108.
20. Watnick S, Kirwin P, Mahnensmith R, Concato J. The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 2003; 41(1): 105-110.
21. Smith MD, Hong BA, Robson AM: Diagnosis of depression in patients with end-stage renal disease. Comparative analysis. Am J Med. 1985; 79: 160-166.
22. Grant D, Almond MK, Newnham A et al. The Beck Depression Inventory requires modification in scoring before use in a haemodialysis population in the UK. Nephron Clin Pract 2008; 110: 33-38.
23. Theofilou PA. Sexual functioning in chronic kidney disease: the association with depression and anxiety. Hemodial Int 2012; 16(1): 76-81.
24. Song MK, Ward SE, Hladik GA et al. Depressive symptom severity, contributing factors, and self-management among chronic dialysis patients. Hemodial Int 2016; 20: 286-292.
25. Di Lullo L, Rivera R, Barbera V et al. Sudden cardiac death and chronic kidney disease: from pathophysiology to treatment strategies. Int J Cardiol 2016; 217: 16-27.
26. Cukor D, Rosenthal DS, Jindal RM et al. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int 2009; 75: 1223-1229.
27. Koo JR, Yoon JW, Kim SG et al. Association of depression with malnutrition in chronic hemodialysis patients. Am J Kidney Dis 2003; 41: 1037-1042.
28. Kimmel PL, Peterson RA. Depression in end stage renal disease patients: Tools, correlates, outcomes and needs. Semin Dial 2005; 18: 91-97.
29. Kimmel PL, Peterson RA, Weihs KL et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57: 2093-2098.
30. Kurella M, Kimmel PL, Young BS et al. Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 2005; 16: 774-781.
31. Walters BA, Hays RD, Spritzer KL et al. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 2002; 40: 1185-1194.
32. Rizk D, Jurkovitz C, Veledar E et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 2009; 43: 560-566.
33. Miskulin DC, Abebe KZ, Chapman AB et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis 2014; 63: 214-226.
34. Suwabe T, Ubara Y, Mise K et al. Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. BMC Nephrol 2013; 14: 179.
35. Simms RJ, Thong KM, Dworschak GC et al. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2016; 31(7): 1130-1140.
36. Nagler EV, Webster AC, Vanholder R et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012; 27(10): 3736-3745.
37. Care A, DiMartini C, Crone M et al. Psychiatric aspects of organ transplantation in critical care. Crit Care Clin 2008; 24(4): 949-981.
38. Fischer MJ, Xie D, Jordan N et al. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Studies. Am J Kidney Dis 2012; 60: 27-38.
39. Lopes AA, Albert JM, Young EW et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004; 66: 2047-2053.
40. Nagler EV, Webster AC, Vanholder R et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012; 27: 3736-3745.
41. Eyler RF, Unruh ML, Quinn DK et al. Psychotherapeutic agents in end-stage renal disease. Semin Dial 2015; 28: 417-426.
42. Cohen LM, Levy NB, Tessier EG et al. W: Levenson JL (red). The American Psychiatric Publishing textbook of psychosomatic medicine. 1st ed. Washington: American Psychiatric Publishing 2005: 483-490.
43. Cukor D, Coplan J, Brown C et al. Course of depression and anxiety diagnosis in patients treated with hemodialysis: a 16-month follow-up. Clin J Am Soc Nephrol 2008; 3: 1752-1758.
44. Moreira JM, da Matta SM, Melo e Kummer A et al. Neuropsychiatric disorders and renal diseases: an update. J Bras Nefrol 2014; 36(3): 396-400.
45. Bandelow B, Sher L, Bunevicius R et al. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012; 16: 77-84.
46. Morrison G, Chiang ST, Kopke HH et al. Effect of Renal Imparement on Hemodialysis on lorazepam kinetics. Clin Pharmacol Ther 1984; 35(5): 646-652.
47. Kulesza A, Niemczyk M, Gradzik M. Intracranial Manifestations of Autosomal Dominant Polycystic Kidney Disease. Int J Neurol Res 2016; 2(1): 210-215.
48. Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2002; 13(1): 269-277.
49. Thompson BG, Brown RD Jr, Amin-Hanjani S et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46(8): 2368-2400.
50. Menghini VV, Brown RD Jr, Sicks JD et al. Incidence and prevalence of intracranial aneurysms and hemorrhage in Omsted County, Minnesota 1965 to 1995. Neurology 1998; 51: 405-411.
51. Rinkel GJE. Intracranial aneurysm screening: indications and advice for practice. Lancet Neurology 2005; 4: 122-128.
52. Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 173-180.
53. Niemczyk M, Gradzik M, Niemczyk S et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. AJNR Am J Neuroradiol 2013; 34: 1556-1559.
54. Gieteling EW, Rinkel GJE. Characteristics of intracranial aneurysms and subarachnoid haemorrhage in patients with polycystic kidney disease. J Neurol 2003; 250: 418-422.
55. Schaaf I, Brilstra EH, Rinkel GJE et al. Quality of Life, Anxiety, and Depression in Patients With an Untreated Intracranial Aneurysm or Arteriovenous Malformation. Stroke 2002; 33(2): 440-443.
56. Solheim O, Eloqayli H, Muller TB et al. Quality of life after treatment for incidental, unruptured intracranial aneurysms. Acta Neurochir (Wien) 2006; 148(8): 821-830.
57. Joshwa B, Khakha DC, Mahajan S. Fatigue and depression and sleep problems among hemodialysis patients in a tertiary care center. Saudi J Kidney Dis Transpl 2012; 23: 729-735.
58. Koyama H, Fukuda S, Shoji T et al. Fatigue is a predictor for cardiovascular outcomes in patients undergoing hemodialysis. Clin J Am Soc Nephrol 2010; 5: 659-666.